Genmab A/S ADR (GMAB)

Feb 20, 2025, 8:00 AM EST - 2 days ago

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Feb 19, 2025, 9:14 AM EST - 3 days ago

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Feb 18, 2025, 2:25 AM EST - 4 days ago

Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon

JNJ

Feb 14, 2025, 9:32 AM EST - 8 days ago

Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript

Feb 13, 2025, 6:00 AM EST - 9 days ago

Notice to Convene the Annual General Meeting of Genmab A/S

Feb 12, 2025, 1:14 PM EST - 10 days ago

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Feb 12, 2025, 11:01 AM EST - 10 days ago

Genmab Publishes 2024 Annual Report

Jan 23, 2025, 3:08 PM EST - 4 weeks ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Jan 22, 2025, 6:23 AM EST - 4 weeks ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Jan 3, 2025, 1:56 PM EST - 7 weeks ago

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:20 AM EST - 2 months ago

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Dec 9, 2024, 12:00 PM EST - 2 months ago

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Dec 8, 2024, 11:00 AM EST - 2 months ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Dec 8, 2024, 8:12 AM EST - 2 months ago

Genmab Is Too Attractive To Ignore

Dec 7, 2024, 7:00 PM EST - 2 months ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Dec 3, 2024, 4:35 PM EST - 2 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Dec 3, 2024, 7:07 AM EST - 2 months ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Nov 25, 2024, 11:06 AM EST - 3 months ago

Genmab to Present at Citi's Global Healthcare Conference

Nov 9, 2024, 4:38 PM EST - 3 months ago

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 11:02 AM EST - 3 months ago

Genmab Announces Financial Results for the First Nine Months of 2024

Nov 6, 2024, 3:17 AM EST - 3 months ago

Genmab: Looking To Manage My Position Around Q3 Earnings

Nov 5, 2024, 1:11 PM EST - 3 months ago

Genmab to Present at Jefferies London Healthcare Conference

Nov 5, 2024, 12:00 PM EST - 3 months ago

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Oct 15, 2024, 6:25 AM EDT - 4 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Oct 4, 2024, 1:55 PM EDT - 5 months ago

Major Shareholder Announcement

Sep 15, 2024, 8:45 AM EDT - 5 months ago

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Aug 26, 2024, 12:26 PM EDT - 6 months ago

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 23, 2024, 11:55 AM EDT - 6 months ago

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

BNTX

Aug 19, 2024, 2:00 PM EDT - 6 months ago

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Aug 13, 2024, 2:53 PM EDT - 6 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Aug 12, 2024, 9:48 AM EDT - 6 months ago

Genmab A/S (GMAB) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:03 AM EDT - 7 months ago

Genmab Announces Financial Results for the First Half of 2024

Aug 8, 2024, 11:00 AM EDT - 7 months ago

Genmab Updates 2024 Financial Guidance

Aug 5, 2024, 5:50 AM EDT - 7 months ago

Genmab Takes Full Control of Acasunlimab Development Program

Jul 17, 2024, 6:25 AM EDT - 7 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

Jun 28, 2024, 2:00 AM EDT - 8 months ago

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Jun 27, 2024, 5:00 PM EDT - 8 months ago

Completion of Share Buy-back Program

Jun 26, 2024, 7:08 PM EDT - 8 months ago

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Jun 24, 2024, 9:55 AM EDT - 8 months ago

Transactions in Connection with Share Buy-back Program

Jun 5, 2024, 12:51 PM EDT - 9 months ago

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 9:00 AM EDT - 9 months ago

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Jun 2, 2024, 5:30 PM EDT - 9 months ago

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Jun 1, 2024, 10:00 AM EDT - 9 months ago

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

BNTX

May 23, 2024, 5:00 PM EDT - 9 months ago

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 21, 2024, 11:10 AM EDT - 9 months ago

Genmab Completes Acquisition of ProfoundBio

May 14, 2024, 10:05 AM EDT - 10 months ago

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

May 2, 2024, 6:05 PM EDT - 10 months ago

Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript

May 2, 2024, 11:01 AM EDT - 10 months ago

Genmab Announces Financial Results for the First Quarter of 2024

Apr 29, 2024, 6:58 PM EDT - 10 months ago

Pfizer, Genmab get full FDA approval for cervical-cancer drug

PFE

Apr 29, 2024, 6:40 PM EDT - 10 months ago

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

PFE